News|Podcasts|November 18, 2026

ACT Brief: Patient Trial Conversations, Measuring Site Burden, and Cosentyx and Wilserdly Approvals

In today’s ACT Brief, we examine why oncologists should lead trial discussions while AI supports patients, how site burden can be measured before it becomes risk, and how FDA approved Cosentyx and Wilserdly for two different conditions.

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

  • In part four of a video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, makes the case that oncologists must lead discussions about randomization and treatment decisions. He says AI can prepare patients beforehand and support them afterward.
  • A new ACT FAQ examines how site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns. Each method catches a different moment, and the gaps between them determine whether teams can act before burden becomes risk to trial quality. It notes that a standardized eSource coordinator survey showed high overall satisfaction, yet perceived query reduction varied widely, a sign that implementation quality matters.
  • FDA approved Novartis’s Cosentyx for adults with a rheumatic condition that causes pain and stiffness in the shoulders, neck, and hips, when steroids have not worked or cannot be tapered. In the Phase III Replenish trial, Cosentyx doubled the likelihood of sustained remission while helping patients taper off steroids. FDA also approved Roche’s Wilserdly with everolimus for advanced breast cancer with a specific gene mutation, reducing the risk of progression or death by 62% in the evERA trial.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.


Related to this article